IHS Chemical Week

Chemical Week Magazine :: Newsbriefs

Merck KGaA eyes pharma acquisitions, biosimilars

6:56 AM MDT | May 23, 2014

Merck KGaA plans to invest €100 million ($137 million) this year in biosimilars, a new business being developed by the company’s Merck Serono unit. Merck also is eyeing pharmaceutical acquisition opportunities, particularly in the United States, following its recent $2.6-billion acquisition of AZ Electronic Materials (CW, May 5/12, p. 21). “The focus of the next two years will be on growth. We are aiming for organic and inorganic growth. The latter includes in-licensing agreements as well as acquisitions,” Karl-Ludwig Kley, chairman of Merck KGaA, told...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa